
Supernus Announces Second Quarter 2020 Financial Results
Total revenue of $126.7 million, including net product sales of $89.7 million for Trokendi XR®, $23.7 million for Oxtellar XR®, and $10.6 million for the acquired Parkinson’s disease (PD) products Operating earnings of $45.5 million Completed acquisition …